Publication: Incidence, Risk Factors, Progression, and Treatment of Endovenous Heat-Induced Thrombosis Class 2 or Greater After Endovenous Radiofrequency Ablation
Issued Date
2019-04-01
Resource Type
ISSN
15244725
Other identifier(s)
2-s2.0-85064239207
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. Vol.45, No.4 (2019), 573-580
Suggested Citation
Nuttawut Sermsathanasawadi, Wacharaphong Pitaksantayothin, Nattawut Puangpunngam, Khamin Chinsakchai, Chumpol Wongwanit, Pramook Mutirangura, Chanean Ruangsetakit Incidence, Risk Factors, Progression, and Treatment of Endovenous Heat-Induced Thrombosis Class 2 or Greater After Endovenous Radiofrequency Ablation. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. Vol.45, No.4 (2019), 573-580. doi:10.1097/DSS.0000000000001724 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51742
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Incidence, Risk Factors, Progression, and Treatment of Endovenous Heat-Induced Thrombosis Class 2 or Greater After Endovenous Radiofrequency Ablation
Other Contributor(s)
Abstract
BACKGROUND: Endovenous heat-induced thrombosis (EHIT) is a thrombus that extends from an ablated saphenous vein into the common femoral vein after endovenous radiofrequency ablation (RFA). OBJECTIVE: To investigate the incidence, progression, treatment, and risk factors associated with EHIT-2 or greater after RFA. MATERIALS AND METHODS: This retrospective study included patients diagnosed with symptomatic superficial venous incompetence that were treated by RFA of the great saphenous vein or anterior accessory saphenous vein during the July 2012 to December 2016 study period. Duplex ultrasound scanning was performed at 1 week, 1 month, 3 months, and every year after RFA to detect EHIT. RESULTS: A total of 317 legs from 274 patients were included. The incidence of EHIT-2 or greater was 7.0%, including 5.4% EHIT-2, 1.3% EHIT-3, and 0.3% EHIT-4. No symptomatic pulmonary embolism was found. The independent risk factors for EHIT-2 or greater were vein diameter (p = .027) and concomitant sclerotherapy (p = .037). CONCLUSION: The risk factors found to be independently associated with EHIT-2 or greater were large vein size and concomitant sclerotherapy. Screening for EHIT should be performed in patients with one or both of these risk factors within 1 week after RFA and in patients with postoperative symptoms suggestive of venous thromboembolism.